Novo Nordisk recently announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.聽Novo Nordisk expects to launch REBINYN in the U.S. in the first half of 2018.

For more info on REBINYN, read the full press release here.

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.